Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

Olema Pharmaceuticals is supported by a differentiated pipeline that addresses major unmet need in ER+/HER2- breast cancer, where palazestrant has already shown encouraging Phase 1b/2 activity, including mPFS of 15.5 months overall and 9.2 months in ESR1wt patients. Commercial validation is also improving as Inluriyo reached $75M in 2Q26 and an annualized run rate of about $300M, suggesting strong physician and payer acceptance of oral SERD therapy and lowering launch risk for Olema. In addition, OP-3136 has shown 68% tumor shrinkage, 3 PRs among 19 evaluable patients, no DLTs, and collaboration support from Pfizer and Bayer, reinforcing the company’s capital-efficient, multi-asset optionality.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company facing a negative setup because its value is still dependent on unproven pipeline assets while operating losses are widening. In 2Q26, total operating expenses rose to $67.2M and EPS was ($0.61), with spending expected to keep increasing through 2026 as Phase 3 OPERA-01 and OPERA-02 and the Phase 1 OP-3136 trial advance. The delay in topline OPERA-01 data pushes palazestrant commercialization to 2028, while risks remain that OPERA-01 or OPERA-02 fails to show benefit in ESR1wt or that safety issues and further delays could undermine the program.